MAGNETOM Free.Max, MAGNETOM Free.Star
Siemens Medical Solutions USA, Inc. • Radiology • 06/24/2022
Device Purpose
The MAGNETOM Free.Max and MAGNETOM Free.Star systems, equipped with syngo MR XA50A software, are 0.55 Tesla magnetic resonance diagnostic devices intended for producing cross-sectional images to assist in diagnosis. These devices feature updated hardware, including distinct bore sizes (80cm for Free.Max, 60cm for Free.Star) and new coils, along with enhanced software such as automated shoulder protocols and advanced perfusion imaging capabilities, to improve diagnostic workflow and imaging options.
Summary
The MAGNETOM Free.Max and the newly introduced MAGNETOM Free.Star are magnetic resonance diagnostic devices utilizing the syngo MR XA50A software platform. Both systems operate at a field strength of 0.55 Tesla and are designed to produce transverse, sagittal, coronal, and oblique cross-sectional images of the head, body, or extremities to aid in diagnosis. A primary distinction between the two is bore size, with the MAGNETOM Free.Max featuring an 80 cm patient bore and the MAGNETOM Free.Star a 60 cm bore, necessitating modifications to the Free.Star's gradient system, body coil, and system cover. Both systems can utilize contrast agents depending on the region of interest, and the derived images and physical parameters are intended for interpretation by trained physicians. This iteration introduces several hardware and software enhancements. Hardware updates include an optional dual Scanner User Interface (SUI), an upgraded myExam 3D Camera with automatic patient height, weight, and orientation detection, a new higher-resolution patient video system, and the new Contour M Coil for both systems, while the MAGNETOM Free.Max also offers a new high-load patient table. Software advancements feature the myExam Autopilot extended to shoulder examinations (myExam Shoulder Autopilot), migrated functionalities such as the EP2D_FID pulse sequence for brain perfusion imaging, Inline Perfusion for real-time parameter map calculation, and Access-i for third-party workstation connectivity. Additionally, scan assistance for off-center imaging has been modified. The performance and safety of these new and modified features were assessed through non-clinical testing, including sample clinical image evaluation, coil performance benchmarks, and software verification and validation.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the image quality and diagnostic capability of the 0.55 Tesla MAGNETOM Free platform, specifically with the new syngo MR XA50A software, compare to higher field strength MRI systems for challenging applications like neuroimaging or small joint assessment?; What specific improvements in scan time, image consistency, or ease of use does the myExam Shoulder Autopilot offer compared to manual shoulder MRI protocols?; Are there any limitations or specific patient cohorts for whom the 60cm bore of the MAGNETOM Free.Star might be less suitable compared to the 80cm bore of the MAGNETOM Free.Max, despite hardware modifications for the smaller bore?; What are the quantitative performance metrics (e.g., accuracy, reproducibility) of the migrated EP2D_FID and Inline Perfusion features for brain perfusion imaging on this 0.55T platform?; How does the new Contour M Coil perform across various anatomies in terms of signal-to-noise ratio, coverage, and patient comfort, and what are its primary applications?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of SaaSBOM, HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly